Impilo has closed its second investment pool
Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing…
Mallax acquires Sana Pharma Medical and creates a new Nordic
Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic…
Impilo’s divestment of NutraQ to Orkla completed
On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading…
Aeglea BioTherapeutics and Immedica Announce Commercialization
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLAeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzymeE)
Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research
Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been…
Immedica and WinHealth enter agreement giving Winhealth rights to
Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which…
Impilo and Anders Larnholt form a partnership to create a new pan‐
Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax…
Immedica acquires the rights for Ravicti® and Buphenyl® for Japan
Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol…
PharmaMar signs an agreement with Immedica
PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and…
The Swedish Financial Supervisory Authority has approved the consortium
